Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor

Add time:08/12/2019    Source:sciencedirect.com

The bromodomain and extra-terminal (BET) family of proteins, consisting of the bromodomains containing protein 2 (BRD2), BRD3, BRD4, and the testis-specific BRDT, are key epigenetic regulators of gene transcription and has emerged as an attractive target for anticancer therapy. Herein, we describe the discovery of a novel potent BET bromodomain inhibitor, using a systematic structure-based approach focused on improving potency, metabolic stability, and permeability. The optimized dimethylisoxazole aryl-benzimidazole inhibitor exhibited high potency towards BRD4 and related BET proteins in biochemical and cell-based assays and inhibited tumor growth in two proof-of-concept preclinical animal models.

We also recommend Trading Suppliers and Manufacturers of 4-Iodo-3,5-dimethylisoxazole (cas 10557-85-4). Pls Click Website Link as below: cas 10557-85-4 suppliers

Prev:Regular paperSite-specific gap-misrepair mutagenesis by O4-ethylthymine (cas 10557-55-8)
Next:Research paperSynthesis and biological evaluation of GPR40/FFAR1 agonists containing 3,5-dimethylisoxazole)